UAE Researchers Identify Blood Cancer Drug Leads Using AI

Key Points

1. UAE-based Insilico scientists identified BTK-targeting compounds designed to degrade a protein supporting some malignant blood cells.
2. The PROTAC molecules remain laboratory-stage leads and require extensive preclinical testing before possible human trials.
3. The work strengthens Abu Dhabi’s push to build local biotechnology, scientific talent and intellectual property around artificial intelligence.

The latest

Researchers at Insilico Medicine’s Masdar City operations have used artificial intelligence to develop a new class of drug candidates for certain blood cancers, with the laboratory-stage compounds targeting Bruton’s tyrosine kinase, or BTK. Published in the Journal of Medicinal Chemistry, the work produced lead compounds considered promising enough for further development but not yet ready for human testing. The project adds to an expanding pipeline from the company’s Abu Dhabi research base as the emirate invests in AI-driven biotechnology and life sciences.

Details

• AI discovery: Insilico uses PandaOmics to analyse biological data and identify disease-related proteins, while Chemistry42 generates and evaluates molecules designed to interact with selected targets. Organic chemist Ahmad Alghaith said AI is intended to raise success rates while reducing time and costs. The company selects a potential drug for further testing in 12 to 18 months, versus an estimated two and a half to four years through traditional approaches.
• Protein degradation: The compounds are PROTACs, or proteolysis-targeting chimeras. Rather than merely blocking a disease-related protein, they are designed to bring it into contact with the cell’s protein-disposal machinery, causing it to be broken down. Their target, BTK, supports signalling that helps certain B cells survive, grow and function; abnormal B-cell activity features in several blood cancers.
• Clinical pathway: Existing BTK inhibitors treat certain forms of leukaemia and lymphoma, but Insilico’s approach seeks to trigger degradation rather than temporary inhibition. Before any clinical application, the leads must be assessed for toxicity, pharmacology, dosing, absorption and behaviour in living organisms. Sufficient preclinical results would allow a candidate to seek regulatory clearance for Phase I trials focused primarily on human safety and tolerability.
• Abu Dhabi footprint: Insilico established its UAE operations with support from the Abu Dhabi Investment Office. It runs an AI and quantum-computing development centre at the International Renewable Energy Agency headquarters in Masdar City. The operation forms part of Abu Dhabi’s drive to combine investment, research infrastructure and international partnerships while building advanced technology and life-sciences capabilities beyond hydrocarbons.
• Local pipeline: In April, UAE-based researchers announced brain-cancer compounds, including the first drug from Insilico’s UAE operations to be named a preclinical candidate for development toward human testing. In July, the company announced an AI-discovered non-opioid candidate for chronic pain. It plans to unveil further potential drug candidates during the year.

Between the lines

Generative AI can create new molecular designs around desired characteristics, but faster design does not remove biological complexity. Candidates can fail in laboratory work, animal studies or clinical development, making validation the decisive test of whether computationally promising molecules can become medicines.

What’s next

The BTK-targeting PROTACs next face preclinical studies of selectivity, biological effect and toxicity. If results are sufficient, one or more candidates could proceed toward regulatory approval for human trials, a transition that could take several years.